- Precio de cierre del día anterior
139.51 - Apertura
146.25 - Oferta 149.63 x 100
- Demanda 163.26 x 200
- Rango diario
145.00 - 154.48 - Rango de 52 semanas
113.50 - 211.13 - Volumen
306,063 - Volumen prom.
683,750 - Capitalización bursátil (intradiario)
8.428MM - Beta (mensual por 5 años) 0.96
- Índice de relación precio/utilidad (últimos doce meses)
-- - EPS (últimos doce meses)
-0.03 - Fecha de utilidades 12 nov 2024
- Proyección de dividendo y rentabilidad --
- Fecha de exdividendo --
- Est. anual
193.06
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
www.repligen.com1,783
Empleados a tiempo completo
31-diciembre
Fin del año fiscal
Sector
Medical Instruments & Supplies
Industria
Noticias recientes: RGEN
Más detallesInformación general del desempeño: RGEN
Retornos totales acumulados hasta el 12/11/2024, que pueden incluir dividendos u otras distribuciones. El punto de referencia es
.Retorno a la fecha
Retorno en 1 año(s)
Retorno en 3 año(s)
Retorno en 5 año(s)
Comparar con: RGEN
Puedes seleccionar hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.
Estadísticas: RGEN
Más detallesMedidas de valoración
Capitalización bursátil
7.81B
Valor de la empresa
7.75B
Precio/utilidad (últimos 12 meses)
466.37
Precio/beneficio estimado
78.12
Índice PEG (cálculo de 5 años)
--
Precio/Ventas (ttm)
13.00
Precio/reserva (TMR)
3.93
Valor de la empresa/Ingresos
12.86
Valor de la empresa/BAIIDA
84.25
Actividad financiera destacada
Rentabilidad y estado de resultados
Margen de ganancia
-0.32%
Retorno de activos (ttm)
0.19%
Retorno sobre el capital (ttm)
-0.10%
Ingresos (ttm)
602.35M
Ingresos netos disponibles (ttm)
-1.9M
BPA diluido (ttm)
-0.03
Balance general y flujo de efectivo
Caja total (TMR)
809.15M
Deuda/capital total (TMR)
37.40%
Flujo de caja disponible apalancado (ttm)
120.45M